

Resource Summary Report

Generated by [RRID](#) on Aug 14, 2026

Human ULBP-2/5/6 APC-conjugated Antibody

RRID:AB_2257142

Type: Antibody

Proper Citation

R and D Systems Cat# FAB1298A, RRID:AB_2257142

Antibody Information

URL: http://antibodyregistry.org/AB_2257142

Proper Citation: R and D Systems Cat# FAB1298A, RRID:AB_2257142

Target Antigen: ULBP-2/5/6

Host Organism: Mouse

Clonality: monoclonal

Comments: Applications: Flow Cytometry

Antibody Name: Human ULBP-2/5/6 APC-conjugated Antibody

Description: This monoclonal targets ULBP-2/5/6

Target Organism: Human

Clone ID: 165903

Antibody ID: AB_2257142

Vendor: R and D Systems

Catalog Number: FAB1298A

Record Creation Time: 20250820T055502+0000

Record Last Update: 20250820T224828+0000

Ratings and Alerts

No rating or validation information has been found for Human ULBP-2/5/6 APC-conjugated Antibody.

No alerts have been found for Human ULBP-2/5/6 APC-conjugated Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Li YR, et al. (2026) Spatiotemporal profiling reveals distinct dynamics and checkpoint regulations of CAR-T and CAR-NKT cells against solid tumors. Signal transduction and targeted therapy, 11(1).

Pi R, et al. (2025) Nkp30 and NKG2D contribute to natural killer cell-mediated recognition of HIV-infected cells. iScience, 28(10), 113548.

Li YR, et al. (2025) Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. Med (New York, N.Y.), 100804.

Benjamin JS, et al. (2025) 23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation. Cancer research communications, 5(3), 476.

Li YR, et al. (2025) Protocol to profile tumor and microenvironment from ovarian cancer patient samples and evaluate cell-based therapy using in vitro killing assays. STAR protocols, 6(2), 103742.

Mensching L, et al. (2025) HIV-1 infection of macrophages differentially primes NK-cell cytotoxicity and proinflammatory cytokine production. iScience, 28(7), 112879.

Li YR, et al. (2025) Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells. Cell reports. Medicine, 6(9), 102321.

Zheng D, et al. (2025) CD4+ anti-TGF-β CAR T cells and CD8+ conventional CAR T cells exhibit synergistic antitumor effects. Cell reports. Medicine, 6(3), 102020.

Obajdin J, et al. (2024) Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells. Cell reports. Medicine, 5(11), 101827.

Li YR, et al. (2023) Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design. iScience, 26(10), 107952.

Li YR, et al. (2021) Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. Cell reports. Medicine, 2(11), 100449.